Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

Several other equities analysts also recently commented on VRX. Cantor Fitzgerald set a $23.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research note on Wednesday, August 16th. HC Wainwright set a $17.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, August 21st. Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Monday, August 21st. Deutsche Bank set a $19.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, August 21st. Finally, Vetr downgraded shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “sell” rating and set a $13.30 price objective for the company. in a research note on Thursday, August 24th. Six equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $17.72.

Valeant Pharmaceuticals International (NYSE:VRX) traded up $1.49 during midday trading on Tuesday, reaching $21.20. 27,019,422 shares of the company’s stock traded hands, compared to its average volume of 18,377,553. The stock has a market capitalization of $6,870.75, a price-to-earnings ratio of 3.20, a price-to-earnings-growth ratio of 0.54 and a beta of -0.22. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals International has a twelve month low of $8.31 and a twelve month high of $22.81.

In related news, Director John Paulson bought 344,216 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the completion of the acquisition, the director now owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.87% of the company’s stock.

A number of hedge funds have recently modified their holdings of VRX. US Bancorp DE boosted its holdings in Valeant Pharmaceuticals International by 418.4% in the second quarter. US Bancorp DE now owns 15,573 shares of the specialty pharmaceutical company’s stock worth $269,000 after purchasing an additional 12,569 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Valeant Pharmaceuticals International by 2.0% in the second quarter. Great West Life Assurance Co. Can now owns 253,889 shares of the specialty pharmaceutical company’s stock worth $4,383,000 after purchasing an additional 5,013 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Valeant Pharmaceuticals International in the second quarter worth approximately $1,506,000. Legal & General Group Plc boosted its holdings in Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock worth $23,895,000 after purchasing an additional 121,032 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in Valeant Pharmaceuticals International by 58.4% in the second quarter. Blair William & Co. IL now owns 72,866 shares of the specialty pharmaceutical company’s stock worth $1,261,000 after purchasing an additional 26,865 shares during the last quarter. Institutional investors own 49.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/valeant-pharmaceuticals-international-vrx-rating-increased-to-buy-at-valuengine/1760216.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.